NEW YORK, March 26 – Genomics Collaborative has hired GeneticXchange to provide data integration software to the company and its academic collaborators over a period of five-years, the companies said Monday.
The agreement extends a year-old relationship between the two companies, in which Genomics Collaborative (GCI), a Cambridge, Mass., functional genomics company, has non-exclusively licensed gX-Engine, GeneticXchange’s data access and integration software.
In addition, GCI executives will now sit on the product board of GeneticXchange to help direct software development and integrate the two companies R&D, said Jeff Edwards, chief operating officer at GeneticXchange.
“Last year we entered into a small consulting arrangement, but that’s now a five-year collaboration, and [GCI] is making us an integral part of their infrastructure,” said Edwards.
GX-Engine, according to Edwards, allows GCI to access disparate public and proprietary databases and algorithms, combine the information in a standard format, and perform multiple searches.
GCI performs disease association studies, target validation, and tissue-based studies to develop pharmaceutical and pharmacogenomics capabilities.GeneticXchange, based in Menlo Park, Calif., currently has collaborations with Signature Biosciences, a biotechnology company, and several academic research institutions, including Stanford University. In mid-April, the company plans to release a desktop biological pathway visualization and data integration tool, called Pathvision, Edwards said.